BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · Real-Time Price · USD

3.410

-0.040 (-1.16%)

At close: Aug 12, 2026, 4:00 PM EDT

3.500

+0.090 (2.64%)

After-hours: Aug 12, 2026, 7:49 PM EDT

BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Net Income	-42.42	-36.8	-6.81	-26.79	-34.4	-17.24
Depreciation & Amortization	0.16	0.15	0.12	0.02	0.02	0.02
Stock-Based Compensation	1.38	1.08	2.49	2.89	3.94	2.46
Other Adjustments	-0.97	-0.82	-38.85	-2.8	14.94	7.94
Change in Receivables	-	1.02	-1.01	0.01	-0.01	0.01
Changes in Accounts Payable	-2.68	-5.39	8.35	0.87	0.32	-1.75
Changes in Accrued Expenses	0.49	1.04	-0.53	0.26	0.17	-0.98
Changes in Other Operating Activities	-0.29	0.68	2.94	-5.8	-0.98	-0.13
Operating Cash Flow	-42.22	-39.04	-33.32	-31.33	-16	-9.67
Operating Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Capital Expenditures	-	-	-0.63	-	-	-
Purchases of Investments	-31.57	-10.14	-	-	-	-
Other Investing Activities	-0.46	-0.46	-0.31	-	-	-
Investing Cash Flow	-32.03	-10.6	-0.94	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Short-Term Debt Repaid	-	-	-	-	-	-0.3
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-	-0.3
Long-Term Debt Issued	-	-	-	-	-	0.27
Long-Term Debt Repaid	-	-	-	-	-	-0.38
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-0.11
Issuance of Common Stock	56.86	62.98	6.1	5.28	8.34	81.51
Repurchase of Common Stock	-	-	-	-0.06	-13.04	-
Net Common Stock Issued (Repurchased)	56.86	62.98	6.1	5.22	-4.69	81.51
Other Financing Activities	-	-	-	-	-0.1	-
Financing Cash Flow	56.86	62.98	6.1	5.22	-4.8	81.1

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Net Cash Flow	-7.56	13.35	-28.15	-26.11	-20.8	71.43

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Free Cash Flow	-30.82	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-9.62	-66.58	-224.09	-228.03	-120.86	-257.22
Levered Free Cash Flow	-32.34	-28.85	2.62	-23.82	-27.2	-16.42
Unlevered Free Cash Flow	-31.29	-29.74	-25.92	-26.79	-15.65	-9.25

SEC Filings: 10-K · 10-Q